ProShare Advisors LLC Has $869,000 Holdings in Alkermes plc (NASDAQ:ALKS)

ProShare Advisors LLC decreased its position in shares of Alkermes plc (NASDAQ:ALKS) by 20.2% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 36,051 shares of the company’s stock after selling 9,121 shares during the quarter. ProShare Advisors LLC’s holdings in Alkermes were worth $869,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. Signaturefd LLC lifted its holdings in Alkermes by 51.2% in the second quarter. Signaturefd LLC now owns 1,417 shares of the company’s stock valued at $34,000 after buying an additional 480 shares during the period. Hexagon Capital Partners LLC lifted its stake in shares of Alkermes by 3,841.0% in the 2nd quarter. Hexagon Capital Partners LLC now owns 1,537 shares of the company’s stock valued at $37,000 after purchasing an additional 1,498 shares during the period. GAMMA Investing LLC boosted its position in shares of Alkermes by 44.4% during the 2nd quarter. GAMMA Investing LLC now owns 2,287 shares of the company’s stock valued at $55,000 after purchasing an additional 703 shares in the last quarter. CWM LLC grew its stake in Alkermes by 36.7% during the first quarter. CWM LLC now owns 2,732 shares of the company’s stock worth $74,000 after purchasing an additional 733 shares during the period. Finally, Ashton Thomas Private Wealth LLC bought a new stake in Alkermes in the second quarter worth approximately $116,000. 95.21% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Cantor Fitzgerald restated an “overweight” rating and set a $48.00 price target on shares of Alkermes in a report on Monday, September 16th. StockNews.com upgraded shares of Alkermes from a “hold” rating to a “buy” rating in a report on Sunday, July 28th. Robert W. Baird lifted their price target on shares of Alkermes from $37.00 to $38.00 and gave the company an “outperform” rating in a research note on Thursday, July 25th. HC Wainwright increased their price objective on shares of Alkermes from $35.00 to $37.00 and gave the stock a “neutral” rating in a research report on Thursday, July 25th. Finally, JPMorgan Chase & Co. boosted their target price on Alkermes from $31.00 to $32.00 and gave the company a “neutral” rating in a research report on Thursday, July 25th. One research analyst has rated the stock with a sell rating, three have given a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, Alkermes currently has an average rating of “Moderate Buy” and an average target price of $36.70.

Alkermes Stock Performance

Shares of ALKS opened at $27.53 on Friday. The firm has a market capitalization of $4.66 billion, a P/E ratio of 10.88, a P/E/G ratio of 0.59 and a beta of 0.46. Alkermes plc has a 52 week low of $22.01 and a 52 week high of $32.88. The stock has a 50 day moving average price of $27.39 and a two-hundred day moving average price of $25.78. The company has a debt-to-equity ratio of 0.22, a quick ratio of 2.61 and a current ratio of 2.99.

Alkermes (NASDAQ:ALKS) last announced its earnings results on Wednesday, July 24th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.70. The company had revenue of $399.13 million for the quarter, compared to analysts’ expectations of $393.30 million. Alkermes had a return on equity of 23.20% and a net margin of 19.15%. Alkermes’s quarterly revenue was down 35.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.38 earnings per share. Equities analysts forecast that Alkermes plc will post 2.36 earnings per share for the current fiscal year.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.